Neurocrine Biosciences NBIX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's operating income?
- Neurocrine Biosciences (NBIX) reported operating income of $193.4M in Q1 2026.
- How has Neurocrine Biosciences's operating income changed year-over-year?
- Neurocrine Biosciences's operating income increased by 719.5% year-over-year, from $23.6M to $193.4M.
- What is the long-term trend for Neurocrine Biosciences's operating income?
- Over 3 years (2022 to 2025), Neurocrine Biosciences's operating income has grown at a 35.5% compound annual growth rate (CAGR), from $249M to $619.1M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.